Trial Profile

An International, Prospective, Open-label, Multi-center, Randomized Phase III Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) Versus Observation to Delay Castration or Disease Recurrence in Adult Male Patients With Prostate-specific Membrane Antigen (PSMA) Positive Oligometastatic Prostate Cancer (OMPC)

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 28 Aug 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Lutetium (177Lu) vipivotide tetraxetan (Primary) ; Piflufolastat F18 (Primary)
Indications Prostate cancer
Focus Registrational; Therapeutic Use
Acronyms PSMA-DC
Sponsors Novartis Pharmaceuticals

21 Aug 2025 Planned End Date changed from 9 Jul 2030 to 6 Nov 2029.
21 Aug 2025 Planned primary completion date changed from 21 Dec 2027 to 31 Mar 2026.
16 Jun 2025 Planned number of patients changed from 450 to 458.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com